uniQure is delivering on the promise of gene therapy -- single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered adeno-associated virus (AAV)-based gene therapies to treat patients with severe genetic diseases. We are currently conducting a pivotal phase 3 trial in our lead indication, hemophilia B, and have established preclinical proof-of-concept in Huntington’s disease.